Differential expression of anterior gradient gene AGR2 in prostate cancer

BMC Cancer

Table 3 Clinicopathologic parameters and AGR2 expression in patients with high stage prostate cancer

	Stage III/IV patients	Mean AGR2 expression (SE)	P-value	Low AGR2	High AGR2	P-value
Total cases	65	0.53 (0.057)		44	21
Age at surgery			0.762²			0.763¹
Median (range)	66 (50-76)			66 (50-76)	65 (50-73)
Mean	64.6			64.8	64.3
Gleason score			0.098¹			0.161³
2-6	22	0.664 (0.104)		12	10
7-10	43	0.457 (0.066)		32	11
pT stage			0.451¹			0.111³
pT2-pT3a	30	0.565 (0.087)		17	13
pT3b	35	0.495 (0.076)		27	8
Lymph node status			0.118¹			0.480³
Positive	11	0.353 (0.118)		9	2
Negative	54	0.563 (0.064)		35	19
Tumor margins			0.990¹			0.794³
Positive	35	0.536 (0.087)		23	12
Negative	30	0.517 (0.072)		21	9
Capsular invasion			0.805¹			> 0.999³
No invasion	4	0.507 (0.174)		3	1
Invasion	61	0.529 (0.060)		41	20
PSA ng/mL			0.414²			0.089¹
Median (range)	11.9 (2.1-96.5)		0.353¹			0.092³
Mean	18.7
< 10	25	0.607 (0.103)		14	11
≥10	32	0.463 (0.073)		25	7

¹Mann-Whitney, ²Spearman Correlation, ³Fisher's Exact Test. Cases that were uninformative for a given variable were removed from the statistical analysis.

ISSN: 1471-2407